The estimated Net Worth of William D. Waddill is at least $2.97 Million dollars as of 24 July 2024. Mr. Waddill owns over 8,000 units of Arrowhead Pharmaceuticals stock worth over $418,800 and over the last 10 years he sold ARWR stock worth over $2,111,672. In addition, he makes $436,975 as Independent Director at Arrowhead Pharmaceuticals.
William has made over 13 trades of the Arrowhead Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 8,000 units of ARWR stock worth $103,040 on 24 July 2024.
The largest trade he's ever made was selling 26,000 units of Arrowhead Pharmaceuticals stock on 11 May 2020 worth over $950,040. On average, William trades about 3,556 units every 110 days since 2014. As of 24 July 2024 he still owns at least 20,000 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Mr. Waddill stock trades at the bottom of the page.
William D. Waddill serves as Independent Director of the Company. Mr. Waddill began his career 30 years ago in commercial banking and public accounting and has been in the biotechnology industry for over 25 years. Since 2016, he has served on the board of Protagonist Therapeutics, a Newark, CA clinical stage biopharmaceutical company and most recently was Senior Vice President and CFO of Calithera Bioscience, a clinical stage pharmaceutical company from 2014 to 2016. Prior to Calithera, Mr. Waddill was Senior Vice President and CFO at OncoMed Pharmaceuticals from 2007 to 2014. Mr. Waddill served as the Senior Vice President and CFO of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. Before joining Ilypsa, he served as the founder and principal at Square One Finance, a financial consulting business, and Mr. Waddill served as Senior Director of Finance and Administration at Exelixis, Inc., a biotechnology company. Mr. Waddill received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhouseCoopers and Deloitte in Boston.
As the Independent Director of Arrowhead Pharmaceuticals, the total compensation of William Waddill at Arrowhead Pharmaceuticals is $436,975. There are 11 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.
William Waddill is 63, he's been the Independent Director of Arrowhead Pharmaceuticals since 2018. There are 3 older and 14 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.
William's mailing address filed with the SEC is 521 Cottonwood Dr, Milpitas, CA 95035, USA.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: